KIM, Jong-Won,김종원,PARK, Jong-Ho,박종호,WOO, Young-Min,우영민,PARK, Inho,박인호,PARK, Kyung Sun,박경선
申请号：
KRKR2016/012948
公开号：
WO2017/082655A1
申请日:
2016.11.10
申请国别(地区):
WO
年份:
2017
代理人:
摘要：
The present invention relates to a pharmaceutical composition for the prevention or treatment of malignant tumor comprising an agent for inhibiting the expression of HMGCLL1 IS3, a pharmaceutical composition for the prevention or treatment of malignant tumor showing resistance to tyrosine kinase inhibitor, a method for determining a drug resistance in an individual having malignant tumors using the expression level of HMGCLL1 IS3, a composition and a kit for diagnosing drug resistance used for said method, a method for determining the probability of developing malignant tumor using the expression level of HMGCLL1 IS3, a method for screening a malignant tumor therapeutic agent using the expression level of HMGCLL1 IS3, a method for predicting malignant tumor prognosis using the expression level of HMGCLL1 IS3, a composition and a kit for predicting the prognosis of malignant tumor including an agent capable of measuring the expression level of HMGCLL1 IS3, a method for determining drug resistance in an individual having malignant tumor using SNP, a composition and a kit for diagnosing drug resistance used for said method, a method for determining the probability of developing malignant tumor using SNP, a method for predicting malignant tumor prognosis using SNP, and a composition and a kit for predicting the prognosis of malignant tumor used for said method. The method of the present invention can effectively predict or diagnose drug tolerance of chronic myelogenous leukemia and malignant tumor patients, and can further be used for efficient drug therapy and drug development research.La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement dune tumeur maligne comprenant un agent dinhibition de lexpression de HMGCLL1 IS3, une composition pharmaceutique pour la prévention ou le traitement dune tumeur maligne montrant une résistance à un inhibiteur de tyrosine kinase, un procédé de détermination dune résistance médicamenteuse che
